F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Heranova Closes $10M Seed Round for Women’s Health Solutions
Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance
The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...
BrightGene’s Generic Halaven Approved for Marketing in China
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...
Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...
Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37...
Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...
China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
QL Biopharm Raises Series B Funding for Protein Drug Development
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100...